Review of guidelines on primary prevention of cardiovascular disease with aspirin: How much evidence is needed to turn a tanker?

European Journal of Preventive Cardiology

Volumn 21, Issue 3, 2014, Pages 354-365

  Matthys, Frederik ^a   De Backer, Tine ^a   De Backer, Guy ^b   Stichele, Robert Vander ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Aspirin; cardiovascular prevention; evidence; guideline; primary prevention; review

Indexed keywords

ACETYLSALICYLIC ACID;

AUSTRALIA; BIBLIOMETRICS; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DATA BASE; DIABETES MELLITUS; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MEDLINE; MORBIDITY; MORTALITY; NEW ZEALAND; NORTH AMERICA; ORGANIZATION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK REDUCTION; WORLD HEALTH ORGANIZATION;

ASPIRIN; CARDIOVASCULAR PREVENTION; EVIDENCE; GUIDELINE; PRIMARY PREVENTION; REVIEW;

ASPIRIN; CARDIOLOGY; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84896735596     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487312472077     Document Type: Review

References (91)

1. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373: 1849-1860
2. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. adults: behavioral risk factor surveillance system. Am J Prev Med. 2006 ; 30: 74-77
3. Lopez-Carmona D, Bernal-Lopez M, Mancera-Romero J, et al. Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study. Eur J Prev Cardiol. 2012 ; 19: 1074-1081
4. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006 ; 295: 306-313
5. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012 ; 19: 585-667
6. Georg G, Seroussi B, Bouaud J. Extending the GEM model to support knowledge extraction from textual guidelines. Int J Med Inf. 2005 ; 74: 79-87
7. Clinical Knowledge Summaries. Antiplatelet treatment - Management. When should antiplatelet treatment be prescribed for primary prevention of cardiovascular disease? National Institute for Health and Clinical Excellence, 2009.
8. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 Suppl 5: v1-v52.
9. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN, 2007, guideline 97.
10. Scottish Intercollegiate Guidelines Network. Management of diabetes. Edinburgh: SIGN, 2010 guideline 116.
11. Nederlandse Huisartsen Genootschap. Cardiovasculair Risicomanagement. Nederlandse Huisartsen Genootschap, Utrecht, 2006.
12. Domus Medica. Globaal Cardiovasculair risicobeheer. Domus Medica, Antwerpen, 2007.
13. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 ; 150: 396-404
14. Goldstein LB, Bushnell CD, Adams RJ, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 ; 42: 517-584
15. Gilpin VL. Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. (2010). A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association (AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). J Vasc Nurs 2010; 28: 154-155.
16. Cardiovascular disease - primary prevention. Victoria: BC Ministry of Health ; 2008 :
17. Berard L, Booth G, Capes S, et al. Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32 Supplement 1.
18. New Zealand Guidelines Group. New Zealand Cardiovascular guidelines handbook. New Zealand Guidelines Group, New Zealand Ministry of Health, 2009.
19. Hung J. Aspirin for primary prevention. Med J Aust. 2003 ; 179: 147-152
20. Diabetes Australia. Diabetes management in general practice guidelines for type 2 diabetes. Diabetes Australia, Royal Australian College of General Practitioners, Australia, 2011/12.
21. Prevention of cardiovascular disease: Guideline for assessment and management of cardiovascular risk. Geneva: WHO ; 2007 :
22. Algra A, Greving JP. Aspirin in primary prevention: sex and baseline risk matter. Lancet. 2009 ; 373: 1821-1822
23. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010 ; 303: 841-848
24. Evangelista V, Totani L, Rotondo S, et al. Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost. 2005 ; 93: 8-16
25. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009 ; 339: b4531 - b4531
26. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008 ; 337: a1840 - a1840
27. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008 ; 300: 2134-2141
28. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010 ; 55: 2878-2886
29. Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-216.
30. Younis N, Williams S, Ammori B, et al. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother. 2010 ; 11: 1459-1466
31. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2011 ; 107: 1796-1801
32. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010 ; 87: 211-218
33. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care. 2009 ; 32: 2300-2306
34. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992 ; 268: 1292-1300
35. Baigent C, Sudlow C and Collins R. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
36. Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003 ; 163: 2006-2010
37. Hankey GJ, Sudlow CL and Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev 2000; issue 1: Article Id CD001246.
38. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998 ; 351: 1755-1762
39. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002 ; 136: 161-172
40. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 ; 352: 1293-1304
41. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003 ; 26: 3264-3272
42. Sanmuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001 ; 85: 265-271
43. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989 ; 321: 129-135
44. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988 ; 296: 313-316
45. The Medical Research Council's General Practice Research Framework. Lancet. 1998 ; 351: 233-241
46. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001 ; 357: 89-95
47. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol. 2000 ; 57: 326-332
48. Baigent C. Aspirin for everyone older than 50? Against. BMJ. 2005 ; 330: 1442-1443
49. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002 ; 106: 388-391
50. Antiplatelet Trialists' Collaboration. BMJ. 1994 ; 308: 81-106
51. US Preventative Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002; 136: 157-160.
52. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996 ; 348: 1413-1416
53. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 ; 321: 1183-1187
54. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001 ; 52: 563-571
55. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007 ; 8: 21-21
56. British Heart Foundation. ASCEND: A Study of Cardiovascular Events in Diabetes. Available at: http://www.ctsu.ox.ac.uk/ascend (accessed 16 December 2009).
57. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009 ; 150: 405-410
58. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006 ; 4: 22-22
59. Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002 ; 55: 157-163
60. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97: 1837-1847
61. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991 ; 22: 312-318
62. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126: 234S - 264S
63. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006 ; 113: e85 - e151
64. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007 ; 115: 114-126
65. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006 ; 113: e873 - e923
66. Centers for Disease Control and Prevention. National diabetes fact sheet. General information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
67. Silva JA, Escobar A, Collins TJ, et al. Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation. 1995 ; 92: 1731-1736
68. Natarajan A, Zaman AG, Marshall SM. Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res. 2008 ; 5: 138-144
69. Reusch JE. Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?. J Clin Invest. 2003 ; 112: 986-988
70. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 ; 280: 1930-1935
71. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002 ; 346: 2033-2038
72. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984 ; 311: 1206-1211
73. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 ; 330: 1287-1294
74. Colwell JA, Halushka PV, Sarji K, et al. Altered platelet function in diabetes mellitus. Diabetes. 1976 ; 25: 826-831
75. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007 ; 357: 2482-2494
76. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin) its relation to metabolic control. Thromb Res. 2004 ; 113: 101-113
77. Lev EI. Aspirin resistance transient laboratory finding or important clinical entity?. J Am Coll Cardiol. 2009 ; 53: 678-680
78. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin 'resistance'. J Am Coll Cardiol. 2009 ; 53: 667-777
79. Pignone M, Earnshaw S, Tice JA, et al. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 ; 144: 326-336
80. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
81. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 ; 371: 117-125
82. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005 ; 165: 1410-1419
83. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002 ; 105: 1650-1655
84. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ; 336: 973-979
85. Rexrode KM, Lee IM, Cook NR, et al. Baseline characteristics of participants in the Women's Health Study. J Womens Health Gender-Based Med. 2000 ; 9: 19-27
86. Morimoto T, Fukui T, Lee TH, et al. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004 ; 117: 459-468
87. Berger J, Lala A, Krantz MJ, et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: A meta-analysis of randomized trials. Am Heart J. 2011 ; 162: 115-124
88. De Berardis G, Lucisano G, D'Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012 ; 307: 2286-2294
89. Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012 ; 344: e3318 - e3318
90. Norheim OF, Gjelsvik B, Klemsdal TO, et al. Norway's new principles for primary prevention of cardiovascular disease: age differentiated risk thresholds. BMJ. 2011 ; 343: d3626 - d3626
91. Matthys J, De Meyere M, van Driel ML, et al. Differences among international pharyngitis guidelines: not just academic. Ann Fam Med. 2007 ; 5: 436-443